معهد الأمصال الهندي

(تم التحويل من Serum Institute of India)
Underworkmarefa.png
هذه المقالة تحت العمل، لازالت تحتاج لمزيد من التنمية والترجمة.


معهد الأمصال الهندي
النوعخاصة
الصناعة
تأسست1966; 58 years ago (1966
المؤسسسيروس س. پوناوالا
المقر الرئيسيپونه، الهند
نطاق الخدمةعالمية
الأشخاص الرئيسيون
أدار پوناوالا (الرئيس، المدير التنفيذي)
المنتجات
الشركات التابعةVakzine Projekt Management GmbH,[1] Bilthoven Biologicals BV[2]
الموقع الإلكترونيseruminstitute.com

معهد الأمصال الهندي (إنگليزية: Serum Institute of India)، هي شركة تكنولوجيا حيوية وأدوية هندية. وهي أكبر مصنع لقاحات في العالم.[3][4] يقع في مدينة پونه الهندية، وأسسها سيروس پوناوالا عام 1966.[5] الشركة هي إحدى فروع شركة پوناوالا المحدودة للاستثمار والصناعات.[6]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

نظرة عامة

الترجمة من هنا

The Serum Institute of India was founded 1966 in Pune. The company set out to produce immunobiologicals, which were imported into India at high prices. Among the first products the Serum Institute of India manufactured in large quantities were the tetanus antitoxin, snake antivenom, DPT vaccine, and MMR vaccine. The company's product lines was expanded to include different types of vaccines against bacterial or virus infections, combination vaccines, influenza vaccine, and meningococcal vaccine. Besides vaccine the company also manufactures antisera, blood plasma and hormone products. As of 2014 the vaccines manufactured by the Serum Institute of India have been used in international vaccination programes run by the World Health Organization (WHO), UNICEF, and the Pan American Health Organization (PAHO). Today the Serum Institute of India is run by the Poonawalla Group and engages in research, development and manufacturing.[7]

تأسس معهد الأمصال الهندي في پونه. بدأت الشركة إنتاج الأدوية البيولوجية المناعية التي استوردتها الهند بأسعار مرتفعة، وكان من بين المنتجات الأولى التي صنعها معهد الأمصال الهندي بكميات كبيرة المصل المضاد لذيفان الكزاز، مضاد سم الثعابين، ولقاح دي بي تي/ اللقاح الثلاثي البكتيري، و اللقاح الثلاثي ضد الحصبة والنكاف والحصبة الألمانية. تم توسيع خطوط منتجات الشركة لتشمل أنواعًا مختلفة من اللقاح اللقاحات ضد العدوى البكتيرية أو الفيروسية، واللقاح المركب (اللقاحات المركبة)، ولقاح الأنفلونزا، و لقاح المكورات السحائية، وبالإضافة إلى اللقاحات، تُصنِّع الشركة أيضًا منتجات المضادات المصلية وبلازما الدم والهرمونات. لقد استُخدمت اللقاحات التي يصنعها معهد الأمصال الهندي اعتبارًا من عام 2014 في برامج التطعيم الدولية التي تنفذها منظمة الصحة العالمية (WHO) واليونيسف ومنظمة الصحة للبلدان الأمريكية (PAHO). تدير مجموعة بوناوالا الآن معهد الأمصال الهندي، وتنخرط في البحث والتطوير والتصنيع. <مرجع>: [8]


حتى هنا

In 2009 the company began developing an intranasal swine flu vaccine.[9][10] The company's first international acquisition was Bilthoven Biologicals, a pharmaceutical company in Netherlands, in 2012.[11] In 2016, with support from US-based Mass Biologics of University of Massachusetts Medical School, the Serum Institute of India invented a fast-acting anti-rabies agent, Rabies Human Monoclonal Antibody (RMAb), also known as Rabishield.[12][13]

اعتبارا من 2020, the company is the world's largest vaccine producer by number of doses produced,[14] manufacturing around 1.5 billion doses of vaccines each year.[15] The products developed include tuberculosis vaccine Tubervac (BCG), Poliovac for poliomyelitis, and other vaccinations for the childhood vaccination schedule.[16][17][18]


تطوير لقاح كوڤيد-19

The company has tied up with pharma firm AstraZeneca, which is developing a vaccine named ChAdOx1 nCoV-19 in partnership with Oxford University.[19] It is reported that Serum Institute would provide 10 crore (100 million) doses of the vaccine in India and other low and middle-income countries.[20][21][22] It is estimated to be priced at ₹225 (around $3) per dose.[23] In September 2020, trials were halted by DCGI after a volunteer in Oxford developed illness following a dosage, but were soon resumed after consent by the British regulators.[24][25][26] In December 2020, SII sought emergency approval for the vaccine developed with AstraZeneca [27] and got approved a month later.[28]

They have also reached an agreement with Novavax for the development and commercialisation of Novavax’s NVX-CoV2373 COVID‑19 vaccine candidate in India and other low and middle-income countries.[29][30] The company will also produce Codagenix's nasally administered COVID-19 vaccine, CDX-005.[31][32]

انظر أيضاً

المصادر

  1. ^ "Profile". www.vpm-consult.com. Retrieved 2020-07-10.
  2. ^ "Bilthoven Biologicals acquired by Serum Institute of India". www.thepharmaletter.com. Retrieved 2020-07-10.
  3. ^ "Serum Institute of India Pvt. Ltd.: Private Company Information". bloomberg.com. Retrieved 2018-09-30.
  4. ^ "SERUM INSTITUTE OF INDIA PRIVATE LIMITED - Company, directors and contact details". zaubacorp.com (in الإنجليزية). Retrieved 2018-09-30.
  5. ^ "About Us". Serum Institute of India. Retrieved 8 December 2016.
  6. ^ "Poonawalla Investments AND Industries Private Limited Information - Poonawalla Investments AND Industries Private Limited Company Profile, Poonawalla Investments AND Industries Private Limited News on The Economic Times". The Economic Times. Retrieved 2020-07-10.
  7. ^ Burns, Lawton R. (2014). India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing. Cambridge University Press. p. 488-489. ISBN 9781316021217.
  8. ^ Burns, Lawton R. (2014). India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing. Cambridge University Press. p. 488-489. ISBN 9781316021217.
  9. ^ "India developing indigenous swine flu vaccine". The Times of India. Retrieved 1 February 2015.
  10. ^ Kulkarni, Prasad S.; Raut, Sidram K.; Dhere, Rajeev M. (27 October 2014). "A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ®) in India". Human Vaccines & Immunotherapeutics. 9 (1): 122–124. doi:10.4161/hv.22317. PMC 3667925. PMID 23442586.
  11. ^ Unnikrishnan, C. H. (2012-07-04). "Serum Institute buys Bilthoven Biologicals". Livemint (in الإنجليزية). Retrieved 2020-07-01.
  12. ^ "Fast-acting anti-rabies drug set for India launch - Times of India". The Times of India. Retrieved 2016-06-12.
  13. ^ Kulkarni, Prasad S.; Sahai, Ashish; Gunale, Bhagwat; Dhere, Rajeev M (3 March 2017). "Development of a new purified vero cell rabies vaccine (Rabivax-S) at the serum institute of India Pvt Ltd". Expert Review of Vaccines. 16 (4): 303–311. doi:10.1080/14760584.2017.1294068. PMID 28276304. S2CID 3382124.
  14. ^ Reuters Staff (2020-11-23). "Serum Institute to focus on supplying COVID-19 vaccine to India first". Reuters (in الإنجليزية). Retrieved 2020-11-26. {{cite news}}: |author= has generic name (help)
  15. ^ Krishnan, Murali (2020-09-29). "Coronavirus vaccine: Why does India's Serum Institute have a head start?". Deutsche Welle (in الإنجليزية البريطانية). Retrieved 2020-11-26.
  16. ^ "Serum Institute Tubervac (BCG)". Serum Institute of India. Retrieved 2020-06-15.
  17. ^ "Serum Institute Poliovac". Serum Institute of India. Retrieved 2020-06-15.
  18. ^ "Vaccination Schedule". Vaccination as per the National Immunization schedule by Government of India. Retrieved 2020-06-15.
  19. ^ "AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine". The Economic Times. Retrieved 2020-06-15.
  20. ^ "Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries". The Financial Express. 7 August 2020.
  21. ^ Banerjee, Shoumojit (7 July 2020). "Oxford COVID-19 vaccine at least 6 months away from launch: Serum Institute CEO". The Hindu (in الإنجليزية).
  22. ^ "Coronavirus (Covid-19) vaccine latest update: Oxford-AstraZeneca corona vaccine production starts; US says 2 billion doses 'ready to go'". The Indian Express (in الإنجليزية). 10 June 2020.
  23. ^ "Serum Institute of India to provide Covid-19 vaccines through COVAX at Rs 225 a dose". The Indian Express (in الإنجليزية). 7 August 2020.
  24. ^ Sharma, Milan. "Serum Institute halts coronavirus vaccine trials in India after notice from DCGI over volunteer's illness in UK". India Today (in الإنجليزية). Retrieved 2020-09-10.
  25. ^ "Oxford vaccine trial paused as participant falls ill". BBC News (in الإنجليزية البريطانية). 2020-09-09. Retrieved 2020-09-10.
  26. ^ Ghosh, Poulomi (12 September 2020). "Serum Institute to resume Covid-19 vaccine trial after DGCI gives nod". Hindustan Times (in الإنجليزية).
  27. ^ "India will have Covid-19 vaccine within days: AIIMS director". Hindustan Times (in الإنجليزية). 2021-12-31. Retrieved 2020-12-31.
  28. ^ Schmall E, Yasir S (3 January 2021). "India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other". The New York Times. Retrieved 3 January 2021.
  29. ^ "Serum Institute, Novavax in covid vaccine deal, may produce 100 crore doses". Livemint (in الإنجليزية). 7 August 2020.
  30. ^ "Novavax signs COVID-19 vaccine supply deal with India's Serum Institute". Reuters (in الإنجليزية). 5 August 2020.
  31. ^ "Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine". mint (in الإنجليزية). 22 September 2020.
  32. ^ "India's Serum Institute starts manufacturing Codagenix's potential Covid-19 vaccine". Hindustan Times (in الإنجليزية). 22 September 2020.

وصلات خارجية

تمّ الاسترجاع من "https://www.marefa.org/w/index.php?title=معهد_الأمصال_الهندي&oldid=2275772"